What's New in HIV, Hepatitis C, and Hepatitis B?

Brian R. Wood, MD Associate Professor of Medicine University of Washington & AIDS Education and Training Center

September 6, 2019





No financial disclosures or conflicts of interest.

Outline

- Resources for Continuing Education
- What's New and What's Coming?
 - HIV
 - Hepatitis C (HCV)
 - Hepatitis B (HBV)

Resources for HIV & HCV CME/CNE



IDEA INFECTIOUS DISEASES EDUCATION& ASSESSMENT

Developed at the University of Washington, the IDEA platform supports curricula for large-scale infectious disease initiatives, offering rich capabilities for three clinical stakeholder groups



https://idea.medicine.uw.edu

the IDEA platform

utilized by three national infectious disease curriculums

National HIV Curriculum

Provides ongoing, up-to-date information needed to meet the core competency knowledge for prevention, screening, diagnosis, and ongoing treatment and care of HIV.

www.hiv.uw.edu



Addresses the epidemiology, pathogenesis, clinical manifestations, diagnosis, management, and prevention of STDs.

www.std.uw.edu



A comprehensive resource that addresses the diagnosis, monitoring, and management of hepatitis C virus infection.

www.hepatitisc.uw.edu

www.hiv.uw.edu

www.std.uw.edu

www.hepatitisc.uw.edu

Antiretroviral ,

Medications



National HIV Curriculum

Course

Modules

Question Bank

A free educational web site from the University of Washington and the AETC National Coordinating Resource Center.

Contributors

Funded by a grant from the Health Resources and Services Administration

Course Modules

Screening and Diagnosis

This module is for any health care provider who would like to establish core competence in testing for HIV, recognizing acute HIV infection, and linking persons diagnosed with HIV to medical care.

Overview / Quick Reference > Rapidly access info about Screening and Diagnosis

Self-Study CNE/CME Track your progress and receive CE credit

Clinical

Challenges

Tools &

Calculators >

Master

Bibliography

3

HIV Resources >

Question Bank CNE/CME Interactive board-review style questions with CE credit

Clinical Challenges Expert opinions for challenging and controversial cases

Basic HIV Primary Care

The Basic HIV Primary Care module is intended for any clinician who may interact with persons who have HIV infection in a clinical setting, with an emphasis on the primary care management issues related HIV.

Overview / Quick Reference > Rapidly access info about Basic HIV Primary Care

Self-Study CNE/CME Track your progress and receive CE credit **Ouestion Bank CNE/CME** Interactive board-review style questions with CE credit

Clinical Challenges Expert opinions for challenging and controversial cases

To access the National HIV Curriculum go to: www.hiv.uw.edu



Course Modules

Screening and Diagnosis of Hepatitis C Infection

For any clinician who may encounter persons with hepatitis C virus infection and would like to establish core competence in testing for hepatitis C, counseling patients on preventing hepatitis C transmission, and diagnosing acute hepatitis C infection.

Overview / Quick Reference > Rapidly access info about Screening and Diagnosis of Hepatitis C Infection

Self-Study CNE/CME

Track your progress and receive CE credit

Evaluation, Staging, and Monitoring of Chronic Hepatitis C

Overview / Quick Reference > Rapidly access info about Evaluation, Staging, and Monitoring of Chronic Hepatitis C

Self-Study CNE/CME

Track your progress and receive CE credit

chronic hepatitis C infection. Content includes initial evaluation, natural

To access the National Hepatitis C Curriculum go to: www.hepatitisc.uw.edu

What's New in HIV Treatment & Prevention?



What's New in HIV Treatment? KEY POINTS

- Start ART as soon as possible (send genotype resistance assay, but don't wait for results)
- All first-line regimens are now integrase inhibitor based
- A suppressed VL means HIV will not be transmitted!
- Several two-drug (dual) ART options have been approved
- The future of HIV treatment is long-acting ARV's

Start ART as Soon as Possible (Even Same Day as Diagnosis or First Visit)



HHS Antiretroviral Therapy Guidelines: 2018 When to Start ART

Antiretroviral Therapy is Recommended for:

All persons living with HIV, regardless of CD4 count, to reduce morbidity and mortality	
All persons living with HIV to prevent transmission	AI

On a case-by-case basis, ART may be deferred because of clinical and/or psychosocial factors, but therapy should be initiated as soon as possible.

Conditions that increase the urgency of ART: pregnancy; opportunistic infection; CD4 count <200; HIV-associated dementia, malignancy, or nephropathy; HBV/HCV; acute HIV

Source: HHS Antiretroviral Therapy Guidelines. 2018. aidsinfo.nih.gov

Rapid Initiation of ART Rapid Start in SF (Part of "Getting to Zero")

Median Time to Care, ART, and Virologic Suppression

Metric	2013	2014	2015	2016	%∕∆ 2013-2 016
New HIV diagnoses	399	329	295	265	
Met rapid definition (%)	23 (6)	45 (14)	50 (17)	80 (30)	
Diagnosis to care (days)	8	7	7	5	-38%
1 st visit to ART (days)	27	17	6	1	-96%
Diagnosis to VL <200 (days)	134	92	77	61	-54%

•Rapid ART: visit within 5 days of HIV diagnosis and ART within 1 day of visit

•Visit includes: meeting with SW, benefits counselor, care provider, counselor & pharmacist

•Diagnosis to VL <200 decreased significantly in all groups (gender, race/ethnicity, age, housing)

Bacon O et al. CROI 2018. Abstract 93.



HIV Treatment <u>is</u> Prevention; Undetectable = Untransmittable (<u>U=U</u>)





Undetectable = Untransmittable



Source: Prevention Access Campaign, www.preventionaccess.org

HIV Treatment <u>is</u> Prevention Summary of Data to Date

Study	Methodology	Approx. # CLS Acts	# Linked Transmiss.	HIV Transmission Risk
HPTN 052	ART early versus delayed	-	<u>Zero</u>	93-96% risk reduction
Partner 1	888 serodifferent couples (548 MF couples, 350 MM couples); 1,238 CYFU	58,000	<u>Zero</u>	95% CI 0.0-0.3/100 CYFU (0.0-0.84 for MM couples)
*Partner 2	783 serodifferent couples (all MM); 1,596 CYFU	77,000	<u>Zero</u>	95% CI 0.0-0.23/100 CYFU
Opposites Attract	343 serodifferent couples (all MM); 591 CYFU	17,000	<u>Zero</u>	95% CI 0.0-0.62/100 CYFU

*New data in 2018 MM = male-male, MF = male-female, CLS = condomless sex acts, CYFU = couple years of follow up

Sources: Cohen 2011, Cohen 2016, Roger 2016, Bavinton 2017, Rodger 2018



Key Points About "U=U"

- Powerful message that can reduce stigma
- Important to continue STI prevention counseling
- "Undetectable" in the studies was <200 or <400 copies/mL
- Applies to women living with HIV who become pregnant, sexual transmission among M-F and M-M sexual partners, ?persons who inject drugs (PWID), ?occupational PEP



All First-Line Regimens are Integrase Inhibitor Based



DHHS Guidelines 2018 Recommended Initial Regimens for Most People With HIV

Components (Integrase with 2 NRTI's)	Trade Name	Pill
Dolutegravir-Abacavir-Lamivudine+	Triumeq	572 Tri
Dolutegravir + TAF-Emtricitabine ^{#*}	Tivicay + Descovy	51/2 225
Bictegravir-TAF-Emtricitabine#	Biktarvy	GSI
Raltegravir + TAF-Emtricitabine#*	lsentress + Descovy	227 227 225

⁺Only if HLA-B*5701 negative; caution if history of ischemic CV disease
 [#]TAF ok with creatinine clearance as low as 30 mL/min
 *Options with TAF shown; TDF is also reasonable per HHS guidelines; IAS-USA guidelines favor TAF

Source: HHS Antiretroviral Therapy Guidelines. 2018. aidsinfo.nih.gov

DHHS Guidelines 2018 Recommended Initial Regimens In Certain Clinical Situations

Components

Other Integrase Inhibitor plus 2 NRTI's

Elvitegravir/Cobicistat/Emtricitabine/TAF (Genvoya)

Elvitegravir/Cobicistat/Emtricitabine/TDF (Stribild)

Boosted PI plus 2 NRTI's

Darunavir (with a booster⁺) plus 2 NRTI's*

Atazanavir (with a booster⁺) plus 2 NRTI's*

NNRTI with 2 NRTI's

Efavirenz-TDF-Emtricitabine (Atripla)

Rilpivirine-TAF-Emtricitabine (*Odefsey*) or Rilpivirine/TDF/Emtricitabine (*Complera*)

Doravirine-TDF-Lamivudine (*Delstrigo*)

^{*}Booster can be a combined tablet with cobicistat or a separate ritonavir tablet ^{*}NRTI combinations: TAF-emtricitabine, TDF-emtricitabine, or abacavir-lamivudine

Dual ART for Initial or Maintenance Antiretroviral Therapy Key Trials

Initial ART

- Dolutegravir/lamivudine (PADDLE, ACTG 5353, GEMINI)
- -Boosted darunavir + lamivudine (ANDES)
- Boosted darunavir + rilpivirine (PREZENT)

Maintenance ART

- -Long-acting IM cabotegravir + rilpivirine (ATLAS, ATLAS-2M, FLAIR)
- -Boosted darunavir + dolutegravir (DUALIS)
- Dolutegravir/rilpivirine (SWORD1&2)
- Dolutegravir/lamivudine (LAMIDOL, ASPIRE, TANGO)
- Boosted darunavir + lamivudine (DUAL GESIDA)

Other Trends in ARV Development

- Long-acting agents are coming soon!
 - *IM cabotegravir + rilpivirine-LA
 - Oral eFdA/MK-8591 (Islatravir)
- Novel formulations & delivery systems
 - Implants, injectables, etc.

Concerns:

- Side effects and need for oral lead-in
- Resistance and need for oral tail
- Burden on staff if clinic-administered



IM cabotegravir (Image courtesy of Dr. Landovitz, UCLA)



TAF implant (betablog.org)

How Will Generic ART Change Things?

• Examples:

Lamivudine/TDF (*Cimduo*)
 Efavirenz/lamivudine/TDF (*Symfi, Symfi Lo*)

Questions:

- Will these be widely manufactured?
- How much lower will the cost be?
- For whom is TDF considered acceptable and safe?
- Will insurance make the decision or will practitioners?

Current ART Controversies

- Does dolutegravir increase risk of fetal neural tube defects?
 - Observational study in Botswana found a safety signal (3/1000 with DTG vs 1/1000 with non-DTG)
- <u>Do INSTI's, especially dolutegravir, lead to more weight gain</u> <u>than other ARV's?</u>
 - Confirmed in multiple studies
 - Is this toxicity? Faster return to health? What to do about it?
- Other questions
 - Does abacavir increase risk of ischemic cardiovascular events?
 - Is TAF ok with severe renal impairment?

Sources: Zash et al. IAS 2019, Mexico City, July 2019. Wood BR, CID 2019.

Key Points About OI Prophylaxis & HIV Treatment Monitoring

- Pneumocystis (PCP/PJP) prophylaxis is still important when CD4 count <200 cells/mL
- Guidelines agree that MAC prophylaxis no longer necessary even if CD4 count <50 cells/mL
- After starting ART, continue to follow viral load monthly until undetectable, then every 3-6 months
- Once CD4 count is above 250 cell/mL, stop checking, as long as HIV RNA remains suppressed

Update on HIV Pre-Exposure Prophylaxis (PrEP) & Post-Exposure Prophylaxis (PEP)

HIV Pre-Exposure Prophylaxis (PrEP) KEY POINTS


- Currently FTC/TDF (*Truvada*) is only approved PrEP drug
- FTC/TAF (*Descovy*) may be approved for PrEP soon!
- Other delivery systems, including long acting, are coming
- Intermittent (pericoital or "on-demand") dosing for cisgender men who have sex with men (MSM) remains controversial
- Biggest PrEP challenges: awareness, access, adherence

Key Considerations with HIV PrEP

- HIV PrEP with TDF/FTC is >80-90% effective
- Failures with good adherence are quite rare
- Side effects are generally mild and transient
- Important to screen for HIV before starting
- Individuals continue to have high risk of STI's after starting HIV PrEP – regular screening is important
- TDF/FTC not recommended with any renal insufficiency, but data for TAF/FTC are promising (and NDA submitted)

Sources: PrEP Guidelines, aidsinfo.nih.gov or cdc.gov

CDC released official PrEP guidelines in 2014, and updated them in 2017



Updated! Published March 2018

US Public Health Service

PREEXPOSURE PROPHYLAXIS FOR THE PREVENTION OF HIV INFECTION IN THE UNITED STATES – 2017 UPDATE

A CLINICAL PRACTICE GUIDELINE



reexposure Prophylaxis for the Prevention of HIV infection in the United States – 2017 Update Clinical Practice Guideline Page 1 of 27

http://www.cdc.gov/hiv/pdf/PrEPguidelines2014.pdf https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf

"On-Demand" PrEP for Cisgender MSM

• <u>IPERGAY</u>

- 2 emtricitabine-tenofovir DF (*Truvada*) tabs before sex then 2 in 48 hours after
- Compared to placebo
- Trial stopped; 86% reduction in HIV incidence

PREVENIR

- Open-label; men opt for daily or on-demand dosing
- About half chose each option
- At mean follow-up 7 months, zero HIV transmissions

Sources: IPERGAY: Molina JM, et al. N Engl J Med 2015;373:2237-46. PREVENIR: Molina JM, et al. IAS Conference, Amsterdam, July 2018.

Controversy Around "On-Demand" PrEP for Cigender MSM

- Not recommended in CDC PrEP Guidelines
- Used in Europe and considered an alternative per IAS-USA
- Issues: how to monitor labs, adherence, and refills?

*Other unanswered PrEP questions:

- Should we be offering generic TDF/3TC as HIV PrEP? CDC guidelines say no, but could improve access

- What is the role of PrEP for a serodifferent couple when the partner with HIV has an undetectable viral load?

- Also, doxycycline shown to be effective for chlamydia and syphilis PrEP and PEP, but should we be offering it?

https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf

HIV PrEP in the Future



Pill

Gel

Vaginal film

Vaginal ring

Injectable

- Tenofovir-containing pills are not feasible for everyone. There is an encouraging pipeline of new PrEP prevention products that will deliver additional options.
- However, we would be naïve to imagine that any one of these will work or be workable for every person.
- What is wanted = prevention *options*.

PrEP Coverage in Washington

 Washington State PrEP DAP (also lists PrEP providers and PrEP navigators)

www.doh.wa.gov/YouandYourFamily/IIInessandDisease/HIVAIDS/ HIVCareClientServices/PrEPDAP

Gilead Medication Assistance Program

www.gilead.com/responsibility/us-patient-iaccess/truvada%20for% 20prep%20medication%20assistance%20program

• Project Inform (flow sheet with additional resources)

http://www.projectinform.org/pdf/PrEP_Flow_Chart.pdf

HIV Post-Exposure Prophylaxis (PEP)

- No dramatic changes
- Same strategy 3-drug ART within 72 hours of exposure
- Preferred regimen <u>TDF/FTC (*Truvada*) + raltegravir or</u> <u>dolutegravir</u>
- Follow up labs at 6 and 16 weeks
- Some outstanding questions: is PEP indicated if source has undetectable viral load? Is TAF/FTC as effective as TDF/FTC?

What's New in HCV Treatment?



Who Should Be Treated for HCV?

- Treatment is recommended for <u>all individuals</u> with HCV (unless very limited life expectancy) because it:
 - -Reduces liver-related complications (ESLD, HCC, decompensation events) and <u>all-cause mortality</u>
 - -Improves symptoms, liver inflammation, and liver fibrosis
 - -Eliminates the risk of transmission to others!
 - -Now generally requires only 2-3 months of oral therapy with >90% chance of SVR (cure) for most individuals!

Who Should be Treated for HCV More Urgently?

- Advanced stage of fibrosis
 - -Especially stage 3 or compensated stage 4 fibrosis
 - If decompensated, need co-management with a specialist
- Symptomatic or systemic complications (cryoglobulinemia, porphyria, lichen planus, arthritis, fatigue, etc)
- HIV or HBV co-infection; other causes of liver disease
- High risk of transmitting to others

Source: hcvguidelines.org

What Evaluation Is Needed Before Treating HCV?

- 1) Need to know treatment-naïve or experienced?
- 2) Labs:
 - -Hepatitis C RNA (viral load) and ?genotype
 - -Baseline CMP (consider CBC, INR)
 - -Hepatitis B serology panel
 - -Very rarely need a resistance test at baseline
- 3) Assessment of fibrosis stage

Assessment of Fibrosis Stage

Liver biopsy

- Also provides assessment of other causes of liver disease (NASH, iron, autoimmune hepatitis, etc)
- Subject to observer variability, sampling error

or...

Non-invasive markers

- Elastography (Fibroscan)
- Direct biomarkers (Fibrosure, Fibrotest)
- Indirect markers (APRI, FIB-4)
- *Usually combine 2 of the above



Another Pre-Treatment Consideration: Risk of Hepatitis B Reactivation

- FDA warning (October 2016)
- 24 cases of hep B reactivation during hep C DAA therapy
 - -2 deaths; 1 liver transplant
- <u>Check hep B serology panel prior to treatment</u>
 - If surface Ag+ start hep B treatment first
 - If only core Ab+ monitor AST/ALT monthly during hep C tx

Source: hcvguidelines.org, fda.gov


TREATMENT OF CHRONIC HEPATITIS C

Guidelines for Treatment-Naïve Individuals (hcvguidelines.org)



DAA: Directly Acting Antiviral

- "PREVIR": protease inhibitors (e.g. glecaprevir, grazoprevir, voxilaprevir)
- "BUVIR": polymerase inhibitors (e.g. sofosbuvir)
- "ASVIR": NS5A inhibitors (e.g. ledipasvir, elbasvir, velpatasvir, pibrentasvir)



Adapted from talk by Dr. Kristen Marks (April 2018, IAS-USA Webinar)

HCV Treatment Recommendations, Updated Sept. 2017 Treatment Naïve Genotype <u>1a</u> Chronic HCV

Treatment Regimen	Duration- No Cirrhosis	Duration- Compensated Cirrhosis	
Sofosbuvir/velpatasvir (<i>Epclusa</i>) 1 tab daily	12 weeks	12 weeks	
Sofosbuvir/ledipasvir (<i>Harvoni</i>) 1 tab daily	*12 weeks	12 weeks	
Glecaprevir/pibrentasvir (<i>Mavyret</i>) 3 tabs daily	8 weeks	12 weeks	
Elbasvir/grazoprevir (<i>Zepatier</i>) 1 tab daily	No NS5A resistance: 12 weeks NS5A resistance: not recommended	No NS5A resistance: 12 weeks NS5A resistance: not recommended	

*8 weeks may be sufficient if HCV RNA <6 million, no HIV infection, and not African American

HCV Treatment Recommendations, Updated Sept. 2017 Treatment Naïve Genotype <u>1b</u> Chronic HCV

Treatment Regimen	Duration- No Cirrhosis	Duration- Compensated Cirrhosis	
Ledipasvir/velpatasvir (<i>Epclusa</i>)	12 weeks	12 weeks	
Ledipasvir/sofosbuvir (<i>Harvoni</i>)	*12 weeks	12 weeks	
Glecaprevir/pibrentasvir (<i>Mavyret</i>)	8 weeks	12 weeks	
Elbasvir/grazoprevir (<i>Zepatier</i>)	12 weeks	12 weeks	

*8 weeks may be sufficient if HCV RNA <6 million, no HIV infection, and not African American

HCV Treatment Recommendations, Updated December 2014 Treatment Naïve Genotype <u>2</u> Chronic HCV

Treatment Regimen	Duration- No cirrhosis	Duration- Compensated Cirrhosis	
Sofosbuvir/velpatasvir (<i>Epclusa</i>)	12 weeks	12 weeks	
Glecaprevir/pibrentasvir (<i>Mavyret</i>)	8 weeks	12 weeks	

HCV Treatment Recommendations, Updated December 2014 Treatment Naïve Genotype <u>3</u> Chronic HCV

Treatment Regimen	Treatment Duration- No Cirrhosis	Treatment Duration- Cirrhosis	
Sofosbuvir/velpatasvir (<i>Epclusa</i>)	12 weeks	12 weeks*	
Glecaprevir/pibrentasvir (<i>Mavyret</i>)	8 weeks	12 weeks	

*Consider resistance testing at baseline and if Y93H mutation present, consider adding ribavirin or using sofosbuvir/velpatasvir/voxilaprevir x 12 weeks

Choosing Between the Regimen Options

- A lot depends on the payer
- Factors may indicate need for one regimen over another:
 - -Decompensated cirrhosis: avoid PI's (so avoid G/P, use a sofosbuvir-based option) *treat with help of a transplant center
 - -Stage 4/5 CKD: avoid sofosbuvir (G/P ok)
 - -Some drug-drug interactions (DDI's) may be a factor

Drug-Drug Interactions

- A comprehensive assessment of all prescribed & OTC meds is recommended prior to initiating treatment
 - -Good resource: <u>http://www.hep-druginteractions.org/</u>
- Examples:
 - -Ledipasvir & velpatasvir interact with PPI's
 - -HCV PI's interact with rifampin, some statins, some anti-epileptics, etc.
 - -There are some interactions with HIV ART (that are surmountable)

Monitoring During and After Hep C Treatment

- Hep C RNA (viral load) at two time points: end of treatment and 12-24 weeks post treatment
 - Optional at 4 weeks of treatment (mostly to assess adherence)
 - Optional 12 months after treatment (consider if cirrhosis or HIV+)
 - Repeat if concern for reinfection at later timepoint
- CMP at 4 weeks
 - Then q4 weeks if concern or if hep B surface Ag+ or isolated core Ab+
- Ongoing surveillance for HCC if cirrhosis present pre-treatment

Medication Access and Patient Assistance

- <u>www.MySupportPath.com</u>, 1-855-7MyPath
- Patient assistance programs for uninsured through drug companies
- Patient Access Network (PAN) Foundation for high deductibles
- HepEducation project (Seattle)

What's New in HBV Treatment & Prevention?



HBV Treatment Options

- Interferon (rarely used)
- Nucleos(t)ides (current standard):
 - Tenofovir alafenamide (TAF)
 - Tenofovir disoproxil fumarate (TDF)
 - Entecavir (ETV)
 - Lamivudine (3TC) (only in combination)

Drugs in phase I/II development siRNAs **ARB-1467** ARB-1740 RG6004 (HBV LNA) ARO-HBV **Entry Inhibitor** Myrcludex B **Capsid Inhibitors** NVR 3-778 **JNJ-56136379** ABI-H0731 AB-423


HBsAg Inhibitors

REP 2139

REP 2165

Source: Kim WR, Advances in Hepatology, Vol 14, July 2018.

Tenofovir DF (TDF) versus Tenofovir alafenamide (TAF)



TDF = tenofovir disoproxil fumarate; TFV = tenofovir

Slide courtesy of Dr. David Spach

Indications for Hepatitis B Treatment No Cirrhosis

HBeAg	HBV DNA	ALT	Treatment Strategy
+	>20,000 IU	<u>≤</u> 2x ULN	 Treatment generally not recommended; may consider if older or family history of HCC, otherwise monitor DNA and ALT
+	>20,000 IU	>2x ULN	 Treat if no spontaneous clearance of eAg after 3-6 months, or immediately if severe hepatitis ETV, TAF, or TDF preferred Continue for at least 12 months after eAg seroconversion
-	>2,000 IU	>2x ULN or 1-2x ULN with liver biopsy or other tests showing moderate/severe inflammation or fibrosis (>F2)	 Treat with ETV, TAF, or TDF Continue until SAg loss Generally several years or indefinite
-	<u><</u> 2,000 IU	<u><</u> ULN	Monitor

Source: Management of Hepatitis B, UpToDate.

Indications for Hepatitis B Treatment Cirrhosis

HBeAg	HBV DNA	ALT	Treatment Strategy
+/-	Detectable	Any	 Treat immediately if decompensated If compensated, treat if HBV DNA >2,000 IU, or ALT elevated ETV, TAF, or TDF indefinitely
+/-	Undetectable	Any	 Observe and monitor HBV DNA and ALT if compensated, refer for transplant eval if decompensated

Source: Management of Hepatitis B, UpToDate.

Hepatitis B The STOP Study

The STOP Study: Design


• **Background**: Randomized, controlled, open-label, phase IV trial

Inclusion Criteria:

- Chronic HBV (sAg+ >6 months)
- Received nucleos(t)ide analog (NA) treatment >12 months
- If eAg positive at start of NA treatment, undetectable HBV DNA for 12 months
- If eAg negative at start of NA treatment, undetectable HBV DNA for 36 months
- No decompensated cirrhosis
- No HIV or HCV coinfection

• Primary Endpoint:

- Response at end of follow up (72 weeks)
- Sustained HBV DNA <2,000, sAg loss



Hepatitis B The STOP Study

Results of the The STOP Study

24%	95%
2%	5%
38%	-
13%	-
27%	_
-	2% 38% 13%

relapse; no benefit was found to stopping NA treatment

Source: Liem KS et al, The Liver Meeting, Nov 2018.

Newest HBV Vaccine: Heplisav[®]

- FDA approved 11/2017 for adults 18+ years
- Only 2-dose adjuvanted Hep B vaccine for adults
- Adjuvant is a phosphorothioate oligonucleotide that targets TLR-9 to enhance antibody response

Table 2: Comparisc			Seroprotection rates (SPR)		
Study	Age range	Sample size	Heplisav-B (95% Cl)	Engerix-B (95% Cl)	Difference in SPRs (95% Cl)
Study 1	18 to 55	Heplisav-B (N=1511) Engerix-B (N=521)	95% (93.9, 96.1)	81.3% (77.8, 84.6)	13.7% (104, 17.5)
Study 2	40 to 70	Heplisav-B (N=1121) Engerix-B (N=353)	90.1% (88.2, 91.8)	70.5% (65.6, 75.2)	19.6% (14.7, 24.8)
Study 3	18 to 70	Heplisav-B (N=5592) Engerix-B (N=2782)	90.0% (87.4, 92.2)	65.1% (59.6, 70.3)	24.9% (19.3, 30.7)

Sources: Halperin SA et al. Vaccine 2012. Heyward WL et al. Vaccine 2013. Jackson S et al. Vaccine 2017. Janssen J et al. Vaccine 2015

Concern for Acute MI Risk

 One of the randomized controlled trials showed increased risk of acute MI

- 0.3% (n=19) with Heplisav-B vs 0.1% (n=3) with Engerix-B
- All had CV risk factors but more in the Heplisav group at CV risk factors
- Conclusions from FDA
 - Acute MI incidence was expected based on CV risk factors
 - No temporal association with vaccine administration
 - Recommended ongoing surveillance post-marketing

ACIP Recommendations for HBV Immunization

Recombivax[®]: 3 dose series (0, 1, 6 months) 10 μg/mL IM (AII)

OR

Engerix[®]: 3 dose series (0, 1, 6 months) 20 μg in 1.0 mL IM (AII)

OR

 Heplisav[®]: 2-dose series (0, 1 month) 20 µg in 0.5 mL IM (CIII)

Assess anti-HB sAb 1-2 months after completion of series

Questions? bwood2@uw.edu

